Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of RNA-targeted therapeutics based on antisense oligonucleotide (ASO) technology. The company operates primarily within the biopharmaceutical and genetic medicine industries, developing drugs that selectively inhibit the production of disease-causing proteins at the RNA level. Ionis’s core business model combines internal drug development with strategic collaborations that generate licensing revenue, milestone payments, and royalties.
The company’s primary revenue drivers include partnered programs with large pharmaceutical companies, royalties from approved medicines, and milestone payments tied to clinical and regulatory progress. Ionis serves global markets, with a strong focus on rare genetic diseases, cardiometabolic disorders, neurological diseases, and select broader population conditions. Its strategic advantage lies in its proprietary antisense technology platform, long-standing expertise in RNA biology, and a diversified pipeline spanning early research through commercial-stage assets. Founded in 1989 as Isis Pharmaceuticals, the company rebranded as Ionis Pharmaceuticals in 2015 to better reflect its scientific focus and global identity.
Business Operations
Ionis operates through a single integrated business model centered on the research, development, and commercialization of antisense-based medicines. Its operations encompass drug discovery, preclinical research, clinical development, regulatory activities, and selective commercialization. Revenue is generated through a combination of collaboration agreements, including upfront payments, research funding, development and regulatory milestones, and ongoing royalties from marketed products developed with partners.
The company maintains full ownership of its antisense technology platform while advancing both wholly owned and partnered programs. Key collaborations have included relationships with large pharmaceutical companies such as Biogen and AstraZeneca, and Ionis also controls multiple wholly owned late-stage programs. The company conducts global clinical trials and relies on contract manufacturing organizations for large-scale production, while retaining control over drug design and development strategy.
Strategic Position & Investments
Ionis’s strategic direction emphasizes advancing a broad pipeline of RNA-targeted therapies while increasingly retaining commercial rights for select wholly owned programs. Growth initiatives include expanding indications for existing compounds, progressing late-stage cardiometabolic and neurological programs, and applying antisense technology to larger patient populations. The company has made targeted investments in internal R&D to enhance delivery technologies and improve tissue specificity of its drugs.
Notable subsidiaries include Akcea Therapeutics, Inc., which was originally established to commercialize Ionis-developed therapies before being fully acquired by Ionis in 2020. Ionis continues to invest in emerging areas such as neurological diseases and cardiometabolic conditions, while maintaining a capital-efficient model through partnerships that offset development risk and funding requirements.
Geographic Footprint
Ionis is headquartered in Carlsbad, California, and operates primarily in North America, with additional clinical, regulatory, and commercial activities extending into Europe, Asia, and other global markets. While its physical operations are concentrated in the United States, the company’s clinical trials and commercial partnerships provide it with a broad international presence.
Through global licensing and collaboration agreements, Ionis’s medicines reach patients across multiple continents. Its international footprint is largely driven by partners responsible for regional commercialization, enabling Ionis to maintain global influence without extensive overseas infrastructure.
Leadership & Governance
Ionis was founded by Stanley T. Crooke, who played a central role in the development of antisense technology and the company’s long-term scientific vision. The current leadership team emphasizes rigorous science, long-term investment in platform technology, and disciplined capital allocation, with a strategic focus on transitioning Ionis toward greater commercial independence.
Key executives include:
- Brett P. Monia – Chief Executive Officer
- Stanley T. Crooke – Founder and Executive Chairman
- Elizabeth L. Hougen – Chief Financial Officer
- Patrick R. O’Neil – Chief Operating Officer
- Richard Geary – Executive Vice President, Research and Development
The leadership team’s philosophy centers on leveraging deep scientific expertise to build a sustainable pipeline of differentiated RNA-targeted therapies while balancing partnered and wholly owned development strategies.